GelMEDIX has announced a global partnership with Catalent, aimed at accelerating the development of regenerative treatments designed to restore vision in patients with serious ocular and retinal diseases.

The biotechnology company, which focuses on cutting-edge regenerative therapies, will tap into Catalent’s expertise in induced pluripotent stem cells (iPSC) and advanced cell-therapy manufacturing. The collaboration will support both the development and clinical manufacturing of GelMEDIX’s iPSC-derived therapies, a rapidly emerging approach to treating degenerative eye conditions.

"Catalent is proud to work with GelMEDIX to support this important clinical program of next-generation therapies for ocular and retinal diseases,” said David McErlane, Biologics Group President at Catalent. “We look forward to supporting these early development efforts and helping bring transformative treatments to patients.”

Through the agreement, GelMEDIX will gain access to Catalent’s proprietary, off-the-shelf, GMP-compliant iPSC cell lines as well as its global manufacturing infrastructure. The partnership is expected to streamline the path from early research to human clinical trials.

“We are excited to partner with Catalent, a leader in developing and manufacturing iPSCs and therapies derived from these cells, to bring our vision-restoring therapies into clinical trials,” said Max Cotler, Chief Executive Officer, GelMEDIX. “Establishing this partnership early positions us to accelerate our progress toward the clinic for our lead programs focused on restoring vision in patients.”

Catalent will also provide end-to-end support for GelMEDIX’s pipeline, including process development, analytical development, manufacturing scale-up, and full GMP production of iPSC-derived therapies across all stages of clinical development.